NCT05864534View on ClinicalTrials.gov

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

August 31, 2026

Conditions
Newly Diagnosed GlioblastomaGlioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeGliosarcomaGlioblastoma Multiforme
Interventions
DRUG

Balstilimab

Balstilimab 450 mg IV over 30 minutes every 3 weeks

DRUG

Botensilimab

Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks

DRUG

Liposomal Doxorubicin

Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks

DEVICE

Sonocloud-9 (SC-9)

Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

Sponsors

Collaborators (2)

Agenus Inc.
CarThera
All Listed Sponsors
collaborator

Agenus Inc.

INDUSTRY

collaborator

CarThera

INDUSTRY

lead

Northwestern University

OTHER

NCT05864534 - Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter